Lampalizumab
Sponsors
Genentech, Inc., Hoffmann-La Roche, Roche Nederland B.V.
Conditions
Geographic Atrophygeographic atrophy secondary to age-related macular degeneration
Phase 2
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
TerminatedNCT01602120
Start: 2012-05-29End: 2018-02-09Updated: 2019-09-11
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
CompletedNCT02288559
Start: 2015-03-30End: 2017-06-02Updated: 2019-09-25
Phase 3
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
TerminatedNCT02247531
Start: 2014-10-06End: 2018-01-23Updated: 2019-10-15
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
TerminatedNCT02247479
Start: 2014-09-18End: 2018-01-29Updated: 2019-06-26
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
TerminatedNCT02745119
Start: 2016-07-21End: 2018-01-31Updated: 2019-03-06
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY
Active, not recruitingNL-OMON46297
Start: 2017-08-17Target: 2Updated: 2024-02-28